Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin

References

• Banatvala JE, Brown DWG. Rubella. Lancet 2004; 363:1127-37; https://doi.org/10.1016/S0140-6736(04)15897-2
   PubMed Web of Science ®Google Scholar
• Papania MJ, Wallace GS, Rota PA, Icenogle JP, Fiebelkorn AP, Armstrong GL, Reef SE, Redd SB, Abernathy ES, Barskey AE. Elimination of endemic measles, rubella, and congenital rubella syndrome from the Western hemisphere: the US experience. JAMA Pediatr 2014; 168:148-55; PMID:24311021; https://doi.org/10.1001/jamapediatrics.2013.4342
   PubMed Web of Science ®Google Scholar
• McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1-34; PMID:23760231
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Global measles and rubella strategic plan: 2012–2020. Geneva; 2012 [accessed 2017 Mar 01]. http://apps.who.int/iris/bitstream/10665/44855/1/9789241503396_eng.pdf.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Vaccine specific coverage among children 19–35 months, National Immunization Survey, 1994–2014. 2015 Aug 27 [accessed 2016 Oct 15]. Available at: http://www.cdc.gov/vaccines/imz-managers/coverage/nis/child/figures/2014-map.html.
   Google Scholar
• Zipprich J, Winter K, Hacker J, Xia D, Watt J, Harriman K. Measles outbreak—California, December 2014–February 2015. MMWR Morb Mortal Wkly Rep 2015; 64:153-4; PMID:25695321
   PubMed Web of Science ®Google Scholar
• Muscat M. Who gets measles in Europe? J Infect Dis 2011; 204:S353-S65; https://doi.org/10.1093/infdis/jir067
   PubMed Web of Science ®Google Scholar
• Clemmons NS, Gastanaduy PA, Fiebelkorn AP, Redd SB, Wallace GS. Measles—United States, January 4–April 2, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:373-6; PMID:25879894
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Measles Cases and Outbreaks. 2017 Feb 09 [accessed 2017 Mar 01]. Available at: http://www.cdc.gov/measles/cases-outbreaks.html.
   Google Scholar
• World Health Organization (WHO). Children in typhoon-hit Tacloban, Philippines, receive vaccines against measles, polio [accessed 2016 Feb 18] http://www.who.int/mediacentre/news/releases/2013/philippines-vaccination-20131126/en/.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Measles-Transmission of measles. 2015 [accessed 2016 Oct 16]. Available at: http://www.cdc.gov/measles/about/transmission.html.
   Google Scholar
• Mumps: the green book, chapter 23 [accessed 2016 Oct 19]. Available at: http://www.gov.uk/government/uploads/system/uploads/attachment_data/file/147975/Green-Book-Chapter-23-v2_0.pdf.
   Google Scholar
• Mufson MA, Diaz C, Leonardi M, Harrison CJ, Grogg S, Carbayo A, Carlo-Torres S, JeanFreau R, Quintero-Del-Rio A, Bautista G, et al. Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12–15 Months. J Pediatric Infect Dis Soc 2015; 4:339-48; PMID:26582873; https://doi.org/10.1093/jpids/piu081
   PubMedGoogle Scholar
• Wellington K, Goa KL. Measles, Mumps, Rubella Vaccine (Priorix™ GSK-MMR). Drugs 2003; 63:2107-26; PMID:12962524; https://doi.org/10.2165/00003495-200363190-00012
   PubMed Web of Science ®Google Scholar
• Rojo CC, Iglesias MRg, Olvera J, Girón MÁ. Study of the immune response engendered by differents combined measles, mumps and rubella (MMR) vaccines in an area of Andalusia (Spain). Vaccine 2003; 22:280-6; https://doi.org/10.1016/S0264-410X(03)00517-6
   PubMed Web of Science ®Google Scholar
• Committee for medicinal products for human use. Guideline on the investigation of manufacturing processes for plasma-derived medicinal products with regard to vcjd risk. 2004 Oct [accessed 2016 Oct 16] http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003741.pdf.
   Google Scholar
• Wiedmann RT, Reisinger KS, Hartzel J, Malacaman E, Senders SD, Giacoletti KE, Shaw E, Kuter BJ, Schodel F, Musey LK. M-M-R((R))II manufactured using recombinant human albumin (rHA) and M-M-R((R))II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children. Vaccine 2015; 33:2132-40; PMID:25796337; https://doi.org/10.1016/j.vaccine.2015.03.017
   PubMed Web of Science ®Google Scholar
• Crovari P, Gabutti G, Giammanco Gt, Dentico P, Moiraghi A, Ponzio F, Soncini R, for the Study TCG. Reactogenicity and immunogenicity of a new combined measles–mumps–rubella vaccine: results of a multicentre trial. Vaccine 2000; 18:2796-803; PMID:10812221; https://doi.org/10.1016/S0264-410X(00)00081-5
   PubMed Web of Science ®Google Scholar
• Stuck B, Stehr K, Bock H. Concomitant administration of varicella vaccine with combined measles, mumps, and rubella vaccine in healthy children aged 12 to 24 months of age. Asian Pac J Allergy Immunol 2002; 20:113-20; PMID:12403196
   PubMed Web of Science ®Google Scholar
• Usonis V, Bakasenas V, Kaufhold A, Chitour K, Clemens R. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children. Pediatr Infect Dis J 1999; 18:42-8; PMID:9951979; https://doi.org/10.1097/00006454-199901000-00011
   PubMed Web of Science ®Google Scholar
• Dine MS, Hutchins SS, Thomas A, Williams I, Bellini WJ, Redd SC. Persistence of vaccine-induced antibody to measles 26–33 years after vaccination. J Infect Dis 2004; 189(Suppl 1):S123-30; PMID:15106101; https://doi.org/10.1086/380308
   PubMed Web of Science ®Google Scholar
• Harmsen T, Jongerius M, Van Der Zwan C, Plantinga A, Kraaijeveld C, Berbers G. Comparison of a neutralization enzyme immunoassay and an enzyme-linked immunosorbent assay for evaluation of immune status of children vaccinated for mumps. J Clin Microbiol 1992; 30:2139-44; PMID:1500523
   PubMed Web of Science ®Google Scholar
• Usonis V, Bakasenas V, Denis M. Neutralization activity and persistence of antibodies induced in response to vaccination with a novel mumps strain, RIT 4385. Infection 2001; 29:159-62; PMID:11440387; https://doi.org/10.1007/s15010-001-1098-7
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Yellow Book, Chapter 3. Infectious diseases related to travel. 2015 Sep 10 [accessed 2016 Oct 25]. Available at: http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/measles-rubeola.
   Google Scholar
• Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Evid Based Child Health 2013; 8:2076-238.
   Google Scholar
• Latner D, Hickman C, Condit RC. Remembering Mumps. PLoS Pathog 2015; 11:e1004791; PMID:25951183; https://doi.org/10.1371/journal.ppat.1004791
   PubMed Web of Science ®Google Scholar
• Pipkin P, Afzal M, Heath A, Minor P. Assay of humoral immunity to mumps virus. J Virol Methods 1999; 79:219-25; PMID:10381091; https://doi.org/10.1016/S0166-0934(99)00019-1
   PubMed Web of Science ®Google Scholar